India, April 22 -- MetaVia Inc. (MTVA), a clinical-stage biotechnology company, Tuesday reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 study of DA-1726 for the treatment of obesity.
The Phase 1 study was designed to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
In the MAD portion of the study, a clear dose-responsive trend in body weight reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Add...